Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04334863 · ClinicalTrials.gov registry record · Phase 1
WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
NCT04334863 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 10 participants.
The verdict
NCT04334863, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant brain tumor that is refractory to standard treatment and is without known cure.
Interventions
- DRUG WP1066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-05-04 |
| Est. Completion | 2023-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04334863
The ClinicalTrials.gov registry entry for NCT04334863 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which WP1066 is the first listed.
NCT04334863 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04334863 about?
NCT04334863 is a clinical study titled "WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors". In this Phase I clinical study, the investigators plan to offer investigational treatment with the novel JAK2/STAT3 inhibitor WP1066 (Moleculin Biotech, Inc.) to pediatric patients with any progressive or recurrent malignant brain tumor that is refractory to standard treatment and is without known c...
What is the current status of trial NCT04334863?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2020-05-04. Estimated completion is 2023-02-03.
What interventions are being tested in trial NCT04334863?
The interventions under investigation include: WP1066 (DRUG).
Who is sponsoring clinical trial NCT04334863?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.